MAP Pharmaceuticals to Present at the 31st Annual J.P. Morgan Healthcare Conference

   MAP Pharmaceuticals to Present at the 31st Annual J.P. Morgan Healthcare
                                  Conference

PR Newswire

MOUNTAIN VIEW, Calif., Jan. 2, 2013

MOUNTAIN VIEW, Calif., Jan. 2, 2013 /PRNewswire/ --MAP Pharmaceuticals, Inc.
(Nasdaq: MAPP) today announced that the Company will present at the 31st
Annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2013 at 3:30
p.m. PT in San Francisco.

A live webcast of the presentation will be available on the Investor Relations
section of MAP Pharmaceuticals' website at http://www.mappharma.com. A replay
also will be available within 24 hours for seven days following the
presentation.

About MAP Pharmaceuticals

MAP Pharmaceuticals is a biopharmaceutical company focused on developing and
commercializing new therapies to address undermet patient needs in neurology.
The Company is developing LEVADEX®, an orally inhaled investigational drug for
the acute treatment of migraine. The New Drug Application for LEVADEX is
currently under review by the U.S. Food and Drug Administration. MAP
Pharmaceuticals has entered into a collaboration agreement with Allergan, Inc.
to co-promote LEVADEX to neurologists and pain specialists in the U.S. and
Canada. The Company also applies its proprietary drug particle and inhalation
technologies to generate new pipeline opportunities by enhancing the
therapeutic benefits of proven drugs, while minimizing risk by capitalizing on
their known safety, efficacy and commercialization history. Additional
information about MAP Pharmaceuticals can be found at
http://www.mappharma.com.

CONTACT:
Lisa Borland
MAP Pharmaceuticals, Inc.
650-386-3122
lborland@mappharma.com

SOURCE MAP Pharmaceuticals, Inc.

Website: http://www.mappharma.com